trending Market Intelligence /marketintelligence/en/news-insights/trending/lAAvB9XPl96P3rcB7aAGBA2 content esgSubNav
In This List

Sarepta Therapeutics elects board member

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Sarepta Therapeutics elects board member

Sarepta Therapeutics Inc. elected Michael Bonney to its board of directors.

Bonney was the CEO of Cubist Pharmaceuticals, up until its acquisition by Merck & Co. Inc. in 2014. He is the CEO and chair of Kaleido Biosciences. He also serves as chair of the boards of Alnylam Pharmaceuticals Inc. and Magenta Therapeutics.